Related Experiment Video

Updated: Aug 9, 2026

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

[Biochemico-pharmacological mechanisms and the relation between the anticalorigenic, hypothermic and antihypoxic

V I Kulinskiĭ, I A Ol'khovskiĭ, A N Kovalevskiĭ

    Voprosy Meditsinskoi Khimii
    |May 1, 1987
    PubMed

    More Related Videos

    Use of a Hanging Weight System for Coronary Artery Occlusion in Mice08:30

    Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

    Published on: April 19, 2011

    In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model08:22

    In vitro Assessment of Myocardial Protection following Hypothermia-Preconditioning in a Human Cardiac Myocytes Model

    Published on: October 27, 2020

    Related Concept Videos

    Adrenergic Agonists: Direct-Acting Agents01:30

    Adrenergic Agonists: Direct-Acting Agents

    Drugs that mimic the action of endogenous catecholamines like noradrenaline and adrenaline are called adrenergic agonists or sympathomimetics. Based on their mechanism of action, sympathomimetics can be classified as direct-, indirect-, or mixed-acting sympathomimetics. Direct-acting adrenergic agonists activate adrenoceptors without affecting presynaptic neurons, making them independent of neuronal catecholamine-depleting agents like reserpine and guanethidine.
    These agents can be classified...
    Adrenergic Agonists: Indirect-Acting Agents01:25

    Adrenergic Agonists: Indirect-Acting Agents

    Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
    One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
    Adrenergic Agonists: Therapeutic Classification01:18

    Adrenergic Agonists: Therapeutic Classification

    Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
    Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
    Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
    Adrenergic Agonists: Therapeutic Uses01:30

    Adrenergic Agonists: Therapeutic Uses

    Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
    Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
    Allergies and anaphylaxis:...
    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

    α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
    α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...